| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ITLN2 |
| Uniprot No | Q8WWU7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-325aa |
| 氨基酸序列 | AAAS SLEMLSREFE TCAFSFSSLP RSCKEIKERC HSAGDGLYFL RTKNGVVYQT FCDMTSGGGG WTLVASVHEN DMRGKCTVGD RWSSQQGNKA DYPEGDGNWA NYNTFGSAEA ATSDDYKNPG YYDIQAKDLG IWHVPNKSPM QHWRNSALLR YRTNTGFLQR LGHNLFGIYQ KYPVKYRSGK CWNDNGPAIP VVYDFGDAKK TASYYSPYGQ REFVAGFVQF RVFNNERAAN ALCAGIKVTG CNTEHHCIGG GGFFPQGKPR QCGDFSAFDW DGYGTHVKSS CSREITEAAV LLFYR |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ITLN2重组蛋白的3篇模拟参考文献及其摘要概括(基于已有研究方向的合理推测，非真实文献)：
---
1. **"Recombinant Human Intelectin-2 Expression and Its Role in Bacterial Recognition"**
*作者：A. Smith, B. Johnson, et al.*
摘要：研究报道了在哺乳动物细胞中成功表达并纯化重组人ITLN2蛋白，证实其通过结合细菌表面特定的糖基化结构(如半乳糖苷)，在先天免疫中发挥病原体识别作用。
2. **"ITLN2 Recombinant Protein Attenuates Adipose Tissue Inflammation in Obesity"**
*作者：L. Zhang, Y. Wang, et al.*
摘要：通过体外实验发现，重组ITLN2蛋白可抑制脂肪细胞中促炎因子(如TNF-α)的分泌，并改善胰岛素敏感性，提示其在肥胖相关代谢紊乱中的潜在治疗价值。
3. **"Structural Characterization of ITLN2 Reveals Calcium-Dependent Carbohydrate Binding"**
*作者：K. Tanaka, M. Yamamoto, et al.*
摘要：利用X射线晶体学解析了重组ITLN2的三维结构，发现其依赖钙离子与特定糖类(如岩藻糖)结合的机制，为设计靶向ITLN2的免疫调节剂提供了结构基础。
---
*注：以上文献为模拟示例，实际研究中建议通过PubMed或Web of Science等数据库检索真实文献。*
**Background of ITLN2 Recombinant Protein**
Intelectin-2 (ITLN2) is a calcium-dependent lectin encoded by the *ITLN2* gene, primarily expressed in human intestinal epithelial cells, adipose tissue, and immune cells. It belongs to the intelectin family, which plays roles in innate immunity by recognizing pathogen-associated glycans, such as galactofuranose residues on microbial surfaces. Structurally, ITLN2 contains a fibrinogen-like domain and forms oligomers, enabling multivalent interactions with ligands. Its function extends beyond pathogen recognition, including modulation of inflammatory responses, adipocyte differentiation, and potential involvement in metabolic disorders like obesity and diabetes.
Recombinant ITLN2 protein is engineered using biotechnological methods, typically by cloning the *ITLN2* gene into expression vectors (e.g., bacterial, mammalian, or insect systems) to produce soluble, functional protein. Purification techniques like affinity chromatography ensure high purity, while quality assessments (e.g., SDS-PAGE, Western blot) confirm structural integrity. Functional validation often involves testing ligand-binding activity (e.g., glycan arrays) or cellular assays to assess immunomodulatory effects.
Research applications of ITLN2 recombinant protein span mechanistic studies of host-pathogen interactions, metabolic regulation, and inflammation. It is also explored for therapeutic potential, such as developing anti-infective agents or treatments for metabolic syndromes. Additionally, ITLN2 serves as a biomarker in diagnostic assays for conditions linked to its dysregulation. Challenges remain in fully elucidating its signaling pathways and clinical relevance, driving ongoing studies to harness its biological roles for medical advancements.
×
